GOSSAMER BIO, INC. Proceeds from Long-Term Debt Issued
GOSSAMER BIO, INC. (GOSS) reported Proceeds from Long-Term Debt Issued of $28.22 million for the 12-month period ending 2019-12-31, per its 10-K filed 2020-03-24.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfLongTermDebt · last filed 2020-08-11
- GOSSAMER BIO, INC. proceeds from issuance of long-term debt for the quarter ending 2019-12-31 was $0.00.
- GOSSAMER BIO, INC. proceeds from issuance of long-term debt for the quarter ending 2019-09-30 was $0.00.
- GOSSAMER BIO, INC. proceeds from issuance of long-term debt for fiscal 2019 was $28.22M.
| Period end | Proceeds from Issuance of Long-term Debt 3 month | Proceeds from Issuance of Long-term Debt 6 month | Proceeds from Issuance of Long-term Debt 9 month | Proceeds from Issuance of Long-term Debt 12 month |
|---|---|---|---|---|
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-24 | $0.00 derived: sum of 2 quarters · filed 2020-03-24 | $28.22M 10-K · filed 2020-03-24 | |
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12 | $28.22M 10-Q · filed 2019-11-12 | ||
| 2019-06-30 | $28.22M 10-Q · filed 2020-08-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 |